Outset Medical Quarterly Balance Sheets Chart
Quarterly
|
Annual
Outset Medical Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | |||||||||||||||
| current assets: | |||||||||||||||
| cash and cash equivalents | 32,176,000 | 68,509,000 | 36,297,000 | 36,388,000 | 36,386,000 | 73,222,000 | 63,877,000 | 75,497,000 | 114,346,000 | 182,348,000 | 230,508,000 | 274,274,000 | 251,767,000 | 294,972,000 | 311,327,000 |
| short-term investments | 194,743,000 | 134,815,000 | 157,701,000 | 186,403,000 | 212,827,000 | 214,280,000 | 163,640,000 | 186,565,000 | 187,921,000 | 157,140,000 | 142,535,000 | 121,934,000 | 25,717,000 | 19,898,000 | 32,888,000 |
| accounts receivable | 36,478,000 | 32,980,000 | 35,493,000 | 36,902,000 | 34,314,000 | 28,070,000 | 22,512,000 | 24,627,000 | 26,899,000 | 25,600,000 | 19,302,000 | 16,411,000 | 12,110,000 | 6,468,000 | 7,082,000 |
| inventories | 55,839,000 | 49,215,000 | 48,257,000 | 44,495,000 | 47,733,000 | 51,476,000 | 55,260,000 | 53,689,000 | 42,873,000 | 39,185,000 | 34,297,000 | 28,882,000 | 24,554,000 | 18,384,000 | 11,810,000 |
| prepaid expenses and other current assets | 6,155,000 | 5,700,000 | 6,026,000 | 5,216,000 | 6,015,000 | 6,597,000 | 4,714,000 | 5,399,000 | 5,387,000 | 5,529,000 | 6,659,000 | 6,459,000 | 7,578,000 | 6,189,000 | 4,717,000 |
| total current assets | 325,391,000 | 291,219,000 | 283,774,000 | 309,404,000 | 337,275,000 | 373,645,000 | 310,003,000 | 345,777,000 | 377,426,000 | 409,802,000 | 433,301,000 | 447,960,000 | 321,726,000 | 345,911,000 | 367,824,000 |
| restricted cash | 3,329,000 | 3,329,000 | 3,329,000 | 3,329,000 | 3,311,000 | 3,311,000 | 33,311,000 | 33,311,000 | 33,311,000 | 33,311,000 | 33,311,000 | 33,311,000 | 33,311,000 | 33,311,000 | 33,311,000 |
| property and equipment | 11,953,000 | 13,273,000 | 13,774,000 | 14,539,000 | 15,189,000 | 15,876,000 | 15,617,000 | 15,245,000 | 13,882,000 | 12,964,000 | 14,532,000 | 15,275,000 | 15,548,000 | 14,998,000 | 14,412,000 |
| operating lease right-of-use assets | 5,029,000 | 5,375,000 | 5,713,000 | 6,042,000 | 5,823,000 | 6,117,000 | 6,405,000 | 6,687,000 | 6,962,000 | 7,231,000 | 7,494,000 | 7,752,000 | 8,004,000 | 8,253,000 | 8,498,000 |
| other assets | 540,000 | 605,000 | 961,000 | 1,128,000 | 1,067,000 | 1,166,000 | 386,000 | 216,000 | 161,000 | 156,000 | 166,000 | 515,000 | 1,240,000 | 1,356,000 | 1,977,000 |
| total assets | 346,242,000 | 313,801,000 | 307,551,000 | 334,442,000 | 362,665,000 | 400,115,000 | 365,722,000 | 401,236,000 | 431,742,000 | 463,464,000 | 488,804,000 | 504,813,000 | 379,829,000 | 403,829,000 | 426,022,000 |
| liabilities and stockholders' equity | |||||||||||||||
| current liabilities: | |||||||||||||||
| accounts payable | 6,773,000 | 5,827,000 | 2,880,000 | 2,217,000 | 1,988,000 | 603,000 | 1,444,000 | 2,753,000 | 5,149,000 | 1,763,000 | 2,702,000 | 2,364,000 | 6,651,000 | 4,948,000 | 5,062,000 |
| accrued compensation and related benefits | 14,248,000 | 19,005,000 | 21,544,000 | 17,461,000 | 14,419,000 | 21,519,000 | 19,273,000 | 15,795,000 | 13,478,000 | 24,948,000 | 17,759,000 | 15,308,000 | 12,602,000 | 16,845,000 | 10,850,000 |
| accrued expenses and other current liabilities | 11,968,000 | 13,459,000 | 12,160,000 | 12,650,000 | 13,893,000 | 16,227,000 | 16,370,000 | 23,261,000 | 18,610,000 | 13,789,000 | 11,389,000 | 9,256,000 | 8,183,000 | 7,903,000 | 8,959,000 |
| accrued warranty liability | 3,200,000 | 3,712,000 | 4,068,000 | 4,168,000 | 3,569,000 | 3,620,000 | 3,456,000 | 3,444,000 | 3,628,000 | 3,704,000 | 3,234,000 | 3,073,000 | 2,860,000 | 2,913,000 | 3,258,000 |
| deferred revenue, current | 12,839,000 | 11,727,000 | 10,828,000 | 10,854,000 | 9,038,000 | 8,662,000 | 7,825,000 | 7,752,000 | 6,833,000 | 6,340,000 | 5,212,000 | 4,373,000 | 3,540,000 | 3,201,000 | 4,132,000 |
| operating lease liabilities, current | 1,642,000 | 1,593,000 | 1,544,000 | 1,474,000 | 1,361,000 | 1,318,000 | 1,276,000 | 1,235,000 | 1,192,000 | 1,151,000 | 1,109,000 | 1,069,000 | 984,000 | 882,000 | 782,000 |
| total current liabilities | 50,670,000 | 55,323,000 | 53,024,000 | 48,824,000 | 44,268,000 | 51,949,000 | 49,644,000 | 55,240,000 | 48,890,000 | 51,695,000 | 41,405,000 | 35,443,000 | 34,820,000 | 36,692,000 | 33,043,000 |
| accrued interest | 1,319,000 | 896,000 | 680,000 | 484,000 | 295,000 | 113,000 | |||||||||
| deferred revenue | 186,000 | 101,000 | 99,000 | 89,000 | 116,000 | 151,000 | |||||||||
| operating lease liabilities | 4,054,000 | 4,482,000 | 4,901,000 | 5,308,000 | 5,220,000 | 5,576,000 | |||||||||
| term loans | 196,813,000 | 130,113,000 | |||||||||||||
| total liabilities | 253,042,000 | 190,915,000 | 155,488,000 | 151,334,000 | 146,379,000 | 154,125,000 | 86,619,000 | 91,472,000 | 86,289,000 | 89,383,000 | 79,053,000 | 73,651,000 | 73,184,000 | 75,220,000 | 71,689,000 |
| commitments and contingencies | |||||||||||||||
| stockholders' equity: | |||||||||||||||
| preferred stock, 0.001 par value; 5,000 shares authorized, and no shares issued and outstanding as of march 31, 2024 and december 31, 2023 | |||||||||||||||
| common stock | 52,000 | 50,000 | 50,000 | 50,000 | 49,000 | 48,000 | 48,000 | 48,000 | 48,000 | 47,000 | 47,000 | 46,000 | 43,000 | 43,000 | 42,000 |
| additional paid-in capital | 1,095,097,000 | 1,084,515,000 | 1,075,413,000 | 1,060,418,000 | 1,049,271,000 | 1,035,456,000 | 1,027,495,000 | 1,017,396,000 | 1,008,940,000 | 1,000,212,000 | 994,486,000 | 985,436,000 | 830,694,000 | 822,624,000 | 816,306,000 |
| accumulated other comprehensive income | -258,000 | -184,000 | -20,000 | -28,000 | -8,000 | 1,000 | 1,000 | ||||||||
| accumulated deficit | -1,001,691,000 | -961,747,000 | -923,147,000 | -876,967,000 | -832,921,000 | -788,950,000 | -747,506,000 | -706,725,000 | -662,886,000 | -625,994,000 | -584,762,000 | -554,292,000 | -524,084,000 | -494,059,000 | -462,016,000 |
| total stockholders' equity | 93,200,000 | 122,886,000 | 152,063,000 | 183,108,000 | 216,286,000 | 245,990,000 | 279,103,000 | 309,764,000 | 345,453,000 | 374,081,000 | 409,751,000 | 431,162,000 | 306,645,000 | 328,609,000 | 354,333,000 |
| total liabilities and stockholders' equity | 346,242,000 | 313,801,000 | 307,551,000 | 334,442,000 | 362,665,000 | 400,115,000 | 365,722,000 | 401,236,000 | 431,742,000 | 463,464,000 | 488,804,000 | 504,813,000 | 379,829,000 | ||
| preferred stock, 0.001 par value; 5,000 shares authorized, and no shares issued and outstanding as of december 31, 2023 and 2022 | |||||||||||||||
| accumulated other comprehensive loss | 68,000 | -253,000 | -393,000 | -113,000 | -564,000 | -934,000 | -955,000 | -649,000 | |||||||
| term loan | 96,784,000 | 96,629,000 | 96,480,000 | 96,336,000 | |||||||||||
| preferred stock, 0.001 par value; 5,000 shares authorized, and no shares issued and outstanding as of september 30, 2023 and december 31, 2022 | |||||||||||||||
| preferred stock, 0.001 par value; 5,000 shares authorized, and no shares issued and outstanding as of june 30, 2023 and december 31, 2022 | |||||||||||||||
| preferred stock, 0.001 par value; 5,000 shares authorized, and no shares issued and outstanding as of march 31, 2023 and december 31, 2022 | |||||||||||||||
| preferred stock, 0.001 par value; 5,000 shares authorized, and no shares issued and outstanding as of december 31, 2022 and december 31, 2021 | |||||||||||||||
| accrued interest, noncurrent | 1,081,000 | 960,000 | 840,000 | 721,000 | 600,000 | 479,000 | 359,000 | 240,000 | 119,000 | ||||||
| deferred revenue, noncurrent | 142,000 | 205,000 | 194,000 | 312,000 | 109,000 | 515,000 | 536,000 | 570,000 | 566,000 | ||||||
| operating lease liabilities, noncurrent | 5,924,000 | 6,261,000 | 6,581,000 | 6,893,000 | 7,199,000 | 7,496,000 | 7,773,000 | 8,044,000 | 8,309,000 | ||||||
| term loan, noncurrent | 29,828,000 | 28,806,000 | 29,784,000 | 29,762,000 | 29,740,000 | 29,718,000 | 29,696,000 | 29,674,000 | 29,652,000 | ||||||
| preferred stock, 0.001 par value; 5,000 shares authorized, and no shares issued and outstanding as of september 30, 2022 and december 31, 2021 | |||||||||||||||
| term loan, current | 1,000,000 | ||||||||||||||
| preferred stock, 0.001 par value; 5,000 shares authorized, and no shares issued and outstanding as of june 30, 2022 and december 31, 2021 | |||||||||||||||
| preferred stock, 0.001 par value; 5,000 shares authorized, and no shares issued and outstanding as of march 31, 2022 and december 31, 2021 | |||||||||||||||
| preferred stock, 0.001 par value; 5,000 shares authorized, and no shares issued and outstanding as of december 31, 2021 and 2020 | |||||||||||||||
| preferred stock, 0.001 par value; 5,000 shares authorized, and no shares issued and outstanding as of september 30, 2021 and december 31, 2020 | |||||||||||||||
| preferred stock, 0.001 par value; 5,000 shares authorized, and no shares issued and outstanding as of june 30, 2021 and december 31, 2020 | |||||||||||||||
| preferred stock, 0.001 par value; 5,000 shares authorized, and no shares issued and outstanding as of march 31, 2021 and december 31, 2020 | |||||||||||||||
| labilities, redeemable convertible preferred stock and stockholders' equity | |||||||||||||||
| redeemable convertible preferred stock | |||||||||||||||
| stockholders' equity | |||||||||||||||
| preferred stock, 0.001 par value; 5,000 shares authorized, and no shares issued and outstanding as of december 31, 2020 and 2019 | |||||||||||||||
| total liabilities, redeemable convertible preferred stock and stockholders' equity | 403,829,000 | 426,022,000 | |||||||||||||
| preferred stock, 0.001 par value; 5,000 shares authorized, and no shares issued and outstanding as of september 30, 2020 and december 31, 2019 |
We provide you with 20 years of balance sheets for Outset Medical stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Outset Medical. Explore the full financial landscape of Outset Medical stock with our expertly curated balance sheets.
The information provided in this report about Outset Medical stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.